News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
LYONS GARY A
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 07/12/2023 |
4
| LYONS GARY A (Director) has filed a Form 4 on RIGEL PHARMACEUTICALS INC|
Txns:
| Granted 25,000 shares
@ $0
Granted 30,000 options to buy
@ $1.32, valued at
$39.6k
|
|
| 05/19/2023 |
4
| LYONS GARY A (Director) has filed a Form 4 on NEUROCRINE BIOSCIENCES INC|
Txns:
| Granted 4,290 options to buy
@ $95.27, valued at
$408.7k
Granted 2,100 restricted stock units
@ $0 |
|
| 05/19/2023 |
4
| LYONS GARY A (Director) has filed a Form 4 on Travere Therapeutics, Inc.|
Txns:
| Granted 4,500 shares
@ $0
Granted 13,500 options to buy
@ $17.11, valued at
$231k
|
|
| 05/02/2023 |
4
| LYONS GARY A (Director) has filed a Form 4 on Eledon Pharmaceuticals, Inc.|
Txns:
| Granted 150,437 options to buy
@ $2.3, valued at
$346k
|
|
| 02/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/02/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/05/2022 |
4
| LYONS GARY A (Director) has filed a Form 4 on NEUROCRINE BIOSCIENCES INC|
Txns:
| Sold 5,000 shares
@ $110.5422, valued at
$552.7k
|
|
| 05/23/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/20/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/12/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/27/2022 |
4
| LYONS GARY A (Director) has filed a Form 4 on NEUROCRINE BIOSCIENCES INC|
Txns:
| Sold 15,000 shares
@ $92.7595, valued at
$1.4M
Exercised 15,000 options to buy
@ $6.66, valued at
$99.9k
|
|
| 02/02/2022 |
4
| LYONS GARY A (Director) has filed a Form 4 on Eledon Pharmaceuticals, Inc.|
Txns:
| Granted 20,000 options to buy
@ $3.97, valued at
$79.4k
|
|
| 10/12/2021 |
4
| LYONS GARY A (Director) has filed a Form 4 on NEUROCRINE BIOSCIENCES INC|
Txns:
| Sold 5,000 shares
@ $105.0587, valued at
$525.3k
|
|
| 06/14/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/14/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/21/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/20/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/18/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/27/2021 |
4
| LYONS GARY A (Director) has filed a Form 4 on NEUROCRINE BIOSCIENCES INC|
Txns:
| Sold 1,600 shares
@ $120.0291, valued at
$192k
Sold 400 shares
@ $120, valued at
$48k
|
|
| 01/05/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/17/2020 |
4
| LYONS GARY A (Director) has filed a Form 4 on Brickell Biotech, Inc.|
Txns:
| Granted 11,934 shares
@ $0.81, valued at
$9.7k
Granted 60,000 options to buy
@ $0.8, valued at
$48k
|
|
| 09/15/2020 |
4
| LYONS GARY A (Director) has filed a Form 4 on Novus Therapeutics, Inc.|
Txns:
| Granted 1,167 options to buy
@ $500, valued at
$583.6k
|
|
| 09/02/2020 |
4
| LYONS GARY A (Director) has filed a Form 4 on Brickell Biotech, Inc.|
Txns:
| Paid exercise price by delivering 346 shares
@ $0.94, valued at
$325.2
Paid exercise price by delivering 8,631 shares
@ $0.94, valued at
$8.1k
Exercised 692 restricted stock units
@ $0 |
|
| 08/04/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/02/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/05/2020 |
4/A
| LYONS GARY A (Director) has filed a Form 4 on Brickell Biotech, Inc.|
Txns:
| Granted 8,333 options to buy
@ $0
Granted 2,167 options to buy
@ $1.16, valued at
$2.5k
|
|
| 06/05/2020 |
4
| LYONS GARY A (Director) has filed a Form 4 on Brickell Biotech, Inc.|
Txns:
| Paid exercise price by delivering 1,746 shares
@ $1.16, valued at
$2k
Paid exercise price by delivering 346 shares
@ $2.93, valued at
$1k
Paid exercise price by delivering 346 shares
@ $1.19, valued at
$411.7
Paid exercise price by delivering 346 shares
@ $1.2, valued at
$415.2
Paid exercise price by delivering 346 shares
@ $1.16, valued at
$401.4
Granted 17,261 shares
@ $0
Exercised 3,491 restricted stock units
@ $0
Exercised 692 restricted stock units
@ $0
Exercised 691 restricted stock units
@ $0
Exercised 692 restricted stock units
@ $0
Exercised 692 restricted stock units
@ $0 |
|
| 05/21/2020 |
4
| LYONS GARY A (Director) has filed a Form 4 on NEUROCRINE BIOSCIENCES INC|
Txns:
| Granted 6,018 options to buy
@ $119.93, valued at
$721.7k
|
|
| 05/19/2020 |
4
| LYONS GARY A (Director) has filed a Form 4 on Retrophin, Inc.|
Txns:
| Granted 3,000 shares
@ $0
Granted 9,000 options to buy
@ $15.43, valued at
$138.9k
|
|
| 05/15/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/19/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/13/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/05/2019 |
4
| LYONS GARY A (Director) has filed a Form 4 on NEUROCRINE BIOSCIENCES INC|
Txns:
| Sold 5,000 shares
@ $100.2207, valued at
$501.1k
|
|
|
|
|